Preclinical News and Research

RSS

Abnormal metabolic pathway drives cancer-cell growth in glioblastoma subtype

A study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has identified an abnormal metabolic pathway that drives cancer-cell growth in a particular glioblastoma subtype. The finding might lead to new therapies for a subset of patients with glioblastoma, the most common and lethal form of brain cancer.

14 Jun 2013

NACC recommendations address established pain therapies and preview potential future advances

Recommendations of the Neuromodulation Appropriateness Consensus Committee (NACC), announced at the 11th World Congress of the International Neuromodulation Society (INS), address established therapies and preview emerging and potential future advances.

13 Jun 2013

New data on PROLOR Biotech's hGH-CTP and MOD-6030 to be presented at ENDO 2013

PROLOR Biotech, Inc., today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its long acting oxyntomodulin (MOD-6030) in preclinical development for the treatment of obesity and type 2 diabetes at ENDO 2013, the 95th Annual Meeting of the Endocrine Society.

13 Jun 2013

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Omeros Corporation today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program.

13 Jun 2013

Study: Stress felt by dad leaves lasting impression on his sperm

Sperm doesn't appear to forget anything. Stress felt by dad-whether as a preadolescent or adult-leaves a lasting impression on his sperm that gives sons and daughters a blunted reaction to stress, a response linked to several mental disorders.

13 Jun 2013

Effective method to restore sight to patients with blinding diseases

Researchers at the University of California, Berkeley, have developed an easier and more effective method for inserting genes into eye cells that could greatly expand gene therapy to help restore sight to patients with blinding diseases ranging from inherited defects like retinitis pigmentosa to degenerative illnesses of old age, such as macular degeneration

13 Jun 2013

Nano-biosensors along with new imaging techniques can improve drug targeting in pancreatic cancer

UK and Australian scientists have been able to show ways in which we can markedly improve drug targeting of solid tumours, using tiny 'biosensors' along with new advanced imaging techniques.

12 Jun 2013

Tumor suppressor p53 inactivation and restoration: an interview with Dr. Xin Lu, Ludwig Institute for Cancer Research

Before we talk about p53, it is important to understand why cancer cells are a problem for the body. Cancer cells multiply recklessly, refuse to die and blithely metastasize to set up shop in places where they don’t belong.

12 Jun 2013

New SPECT and MR imaging systems unveiled at SNMMI's 2013 Annual Meeting

The Society of Nuclear Medicine and Molecular Imaging's 2013 Annual Meetingmarks the unveiling of the successful application of a new preclinical hybrid molecular imaging system-single photon emission tomography and magnetic resonance -which has exceptional molecular imaging capabilities in terms of potential preclinical and clinical applications, technological advancement at a lower cost, and reduction of patient exposure to ionizing radiation.

12 Jun 2013

Understanding Phelan-McDermid Syndrome

In the first prospective study of its kind, Seaver Autism Center researchers at the Icahn School of Medicine at Mount Sinai provide new evidence of the severity of intellectual, motor, and speech impairments in a subtype of autism called Phelan-McDermid Syndrome.

12 Jun 2013

ARIAD Pharmaceuticals initiates ponatinib Phase 2 trial in adult patients with metastatic GIST

ARIAD Pharmaceuticals, Inc. today announced the initiation of the Phase 2 trial of Iclusig (ponatinib) in adult patients with metastatic and/or unresectable gastrointestinal stromal tumors.

11 Jun 2013

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

BioLineRx, a biopharmaceutical development company, announced today that it has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., the leading Chinese pharmaceutical company in the liver disease therapeutic area, for the development and commercialization of BL-8030, an orally available treatment for the Hepatitis C virus.

10 Jun 2013

Concert Pharmaceuticals announces initiation of CTP-354 Phase 1 trial in healthy volunteers

Concert Pharmaceuticals, Inc. today announced that it has initiated a Phase 1 clinical trial with CTP-354. CTP-354 is a novel GABAA receptor subtype-selective modulator that has demonstrated no sedation at therapeutic doses in preclinical models in contrast to existing GABAA receptor non-selective agonists, such as benzodiazepines.

10 Jun 2013

Paragonix Technologies to present Sherpa Pak Cardiac Transport System during ESOT Congress

Paragonix Technologies, Inc. today announced that the European Society for Organ Transplantation accepted for presentation an abstract describing the performance of the Sherpa Pak™ Cardiac Transport System during the upcoming 16th Congress of the European Society for Organ Transplantation to be held in Vienna, Austria from the 8th - 11th September 2013.

10 Jun 2013

Liver regeneration using cell therapy may be possible, study suggests

Liver transplantation is the mainstay of treatment for patients with end-stage liver disease, the 12th leading cause of death in the United States, but new research from the Icahn School of Medicine at Mount Sinai, published in the online journal Cell Stem Cell today, suggests that it may one day become possible to regenerate a liver using cell therapy in patients with liver disease.

10 Jun 2013

Doctors create bioengineered blood vessel and implant it in the arm of kidney disease patient

In a first-of-its-kind operation in the United States, a team of doctors at Duke University Hospital helped create a bioengineered blood vessel and implanted it into the arm of a patient with end-stage kidney disease.

7 Jun 2013

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

6 Jun 2013

BioLineRx starts enrollment in Phase 2 trial of BL-8040 for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase 2 trial for BL-8040, for the treatment of acute myeloid leukemia.

6 Jun 2013

Medicago reports positive interim results from preclinical trial for H7 VLP vaccine candidate

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a preclinical trial for an H7N9 Avian Influenza VLP vaccine candidate ("H7 vaccine").

6 Jun 2013

CytomX collaborates with Pfizer to develop, commercialize more effective antibody-drug conjugates

CytomX Therapeutics, Inc., a biotechnology company developing a new generation of targeted antibody therapeutics, today announced that it has entered into a global strategic collaboration with Pfizer Inc. to develop and commercialize multiple Probody-Drug Conjugates.

6 Jun 2013

Preclinical News and Research

Abnormal metabolic pathway drives cancer-cell growth in glioblastoma subtype

NACC recommendations address established pain therapies and preview potential future advances

New data on PROLOR Biotech's hGH-CTP and MOD-6030 to be presented at ENDO 2013

Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Study: Stress felt by dad leaves lasting impression on his sperm

Effective method to restore sight to patients with blinding diseases

Nano-biosensors along with new imaging techniques can improve drug targeting in pancreatic cancer

Tumor suppressor p53 inactivation and restoration: an interview with Dr. Xin Lu, Ludwig Institute for Cancer Research

New SPECT and MR imaging systems unveiled at SNMMI's 2013 Annual Meeting

Understanding Phelan-McDermid Syndrome

ARIAD Pharmaceuticals initiates ponatinib Phase 2 trial in adult patients with metastatic GIST

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

Concert Pharmaceuticals announces initiation of CTP-354 Phase 1 trial in healthy volunteers

Paragonix Technologies to present Sherpa Pak Cardiac Transport System during ESOT Congress

Liver regeneration using cell therapy may be possible, study suggests

Doctors create bioengineered blood vessel and implant it in the arm of kidney disease patient

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

BioLineRx starts enrollment in Phase 2 trial of BL-8040 for treatment of AML

Medicago reports positive interim results from preclinical trial for H7 VLP vaccine candidate

CytomX collaborates with Pfizer to develop, commercialize more effective antibody-drug conjugates

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics